Matthew Roden

Dr. Matt M. Roden is an Independent Director at iTeos Therapeutics, Inc., an Executive Partner at MPM Capital Inc, a President & Chief Executive Officer at Aktis Oncology, Inc., a President & Director at Celgene Corp. and a Chairman at Turmeric Acquisition Corp. He is on the Board of Directors at iTeos Therapeutics, Inc., Celgene Corp., BioNJ, Inc. and Nextpoint Therapeutics, Inc. Dr. Roden was previously employed as a Senior Vice President & Head-Enterprise Strategy by Bristol Myers Squibb Co., an Executive Director & Analyst by UBS Securities LLC, an Analyst by Merrill Lynch, Pierce, Fenner & Smith, Inc. (Old), a Head-Global Biotechnology Equity Research by UBS Investment Bank (New York), a Vice President by JPMorgan Securities, Inc., an Associate Analyst by Credit Suisse Securities (USA) LLC (Broker), and an Associate by Credit Suisse First Boston. He received his undergraduate degree from George Mason University, a graduate degree from Georgetown University and a doctorate degree from Albert Einstein College of Medicine, Inc..